Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab, Pomalidomide and Dexamethasone for Del(17p) Positive Relapsed and Relapsed/Refractory Multiple Myeloma Patients [DEDALO]

NCT04124497 is registered in ClinicalTrials.gov with Fondazione EMN Italy Onlus as lead sponsor.

NCT NCT04124497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04124497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab, Pomalidomide and Dexamethasone for Del(17p) Positive Relapsed and Relapsed/Refractory Multiple Myeloma Patients [DEDALO]
Lead sponsor
Fondazione EMN Italy Onlus
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 1, 2019
Completion date
July 1, 2027
Enrollment
45 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

deletion 17p syndrome, multiple myeloma